Rigel Pharmaceutical Inc. Stock
Rigel Pharmaceutical Inc. took a tumble today and lost -€0.029 (-3.140%).
Rigel Pharmaceutical Inc. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
Based on the current price of 0.88 € the target price of 13 € shows a potential of 1380.64% for Rigel Pharmaceutical Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Rigel Pharmaceutical Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Rigel Pharmaceutical Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rigel Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | -3.140% | -4.148% | -17.867% | -47.847% | -36.789% | -71.033% | - |
| Ardelyx Inc. | 0.340% | -0.416% | 16.992% | 98.564% | 24.360% | 28.357% | - |
| Evolus Inc | 5.130% | 4.237% | 11.818% | 41.379% | 35.912% | 70.833% | - |
| Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -4.630% | -67.040% | -25.766% | -98.502% | -99.992% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17
Rigel Pharma (RIGL) is a biotechnology and medical research company that plays a crucial role in finding innovative solutions for the healthcare sector. An overview of the financial statements presents a mixed picture, with some positive trends as well as areas of concern.
*Pros: *
Revenues: Rigel Pharma's total revenues have been increasing year over year, with a significant uptick between 2020 and 2021, and a steady increase in 2022. This growth in revenue indicates that the company has been successful in generating profitable sales and expanding its business.
Comments
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for RIGL provided by MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for RIGL provided by MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $3.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RIGL provided by MarketBeat